| HOME >> BIOLOGY >> TECHNOLOGY |
In addition, the company recently announced an agreement with the University of California, Irvine School of Medicine to develop diagnostic tests based on Rosetta's proprietary microRNA technology.
On the scientific front, in a paper published in the April issue of Nature Biotechnology, Rosetta Genomics and collaborators demonstrated the significant potential of microRNAs to be used as biomarkers for diagnosing the primary tumor site in patients with cancer of unknown primary (CUP). The company expects a CUP test based on its microRNA technology to be submitted for regulatory approval by a CLIA certified lab by the end of 2008.
Financial Overview
Operating loss for the first quarter of 2008 was $3.7 million (including a non-cash expense of $191,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $205,000 related to stock based compensation) for the corresponding quarter of 2007. Net loss for the first quarter of 2008 was $3.9 million, or $0.33 per ordinary share, compared with a net loss of $2 million, or $0.23 per ordinary share, for the corresponding quarter of 2007.
Research and development expenses of $2.4 million for the first quarter of 2008, compared to $1.2 million for the first quarter of 2007, remain the Company's largest expense and accounted for 64% of its operating losses.
As of March 31, 2008 we had $18.6 million in cash, cash equivalents, short and long term bank deposits and marketable securities. Our outlook of total cash usage for operating activities for the next nine month of 2008 is approximately $10 million.
As previously announced, the Company continues to receive interest
payments from its auction rate securities, which all but two are rated AAA.
However, due to the
'/>"/>
| SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved |